Analysis of serum folate receptor and antibody level for ovarian cancer detection
卵巢癌检测血清叶酸受体及抗体水平分析
基本信息
- 批准号:7196223
- 负责人:
- 金额:$ 7.4万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-09-19 至 2008-08-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): Currently, only a limited number of serum protein markers exist for a range of tumors, and most have not proved useful for early detection. Membrane-bound folate receptor (FR) alpha is a promising tumor marker for detection of FR alpha-positive tumors. Studies of human tumors show that, FR alpha is over-expressed in epithelial tumors of the ovary, kidney, endometrium, breast and brain compared to normal cells, is identifiable in early disease, increases with tumor progression and stage, and is associated with decreased survival. Importantly, FR alpha is released as a soluble form (sFR alpha) into the circulation and is relatively absent in normal serum, suggesting it may be a promising serum marker for FR alpha-positive tumors. In addition, FR alpha autoantibodies are detected in serum of individuals with folate-related disorders, signifying that the autoantibodies could be another potential biomarker of FR alpha-positive tumors. To our knowledge, no study has investigated their presence in the serum of individuals with FR alpha-positive tumors. We hypothesize that sFR alpha and FR alpha antibodies will be higher among women with ovarian cancer than women without cancer and, specifically, higher among women with early-stage cancer. We focus on ovarian cancer in this application because FR alpha is over-expressed in >90% of non-mucinous epithelial ovarian tumors and is expressed at much lower levels in other tumors; therefore, we anticipate greater likelihood of designing and optimizing assays for FR alpha detection using serum from these patients; and because ovarian cancer is one of the most difficult human diseases to diagnose and treat. Our approach will be to design, develop, and optimize quantitative assays to measure these analytes, and apply each assay to archived, pre-therapeutically collected serum from 30 patients with ovarian cancer (15 early- stage) and 30 women without cancer who participated in a case-control study at Mayo Clinic. Our intent at this initial stage of biomarker discovery is to assess if our assays can detect the analytes truthfully by validating them against FR alpha expression levels in the tumors of the cases and from serum of controls without cancer as reference groups. The data generated from this study, if positive as we expect, will be the basis of a larger analysis that apply these assays to other tumor types with several aims including assessment of diagnostic potential, which is the ultimate goal of biomarker discovery.
描述(由申请人提供):目前,只有有限数量的血清蛋白标记物存在于一系列肿瘤中,并且大多数未被证明对早期检测有用。膜结合叶酸受体(FR) α是一种很有前途的肿瘤标志物,用于检测FR α阳性肿瘤。对人类肿瘤的研究表明,与正常细胞相比,FR α在卵巢、肾脏、子宫内膜、乳房和大脑的上皮性肿瘤中过表达,在疾病早期可识别,随着肿瘤进展和分期而增加,并与生存率降低相关。重要的是,FR - α以可溶性形式(sFR - α)释放到循环中,在正常血清中相对不存在,这表明它可能是FR - α阳性肿瘤的有希望的血清标志物。此外,在叶酸相关疾病患者的血清中检测到FR α自身抗体,这表明自身抗体可能是FR α阳性肿瘤的另一个潜在生物标志物。据我们所知,还没有研究调查它们在FR α阳性肿瘤患者血清中的存在。我们假设sFR α和FR α抗体在患有卵巢癌的女性中比未患癌症的女性更高,特别是在患有早期癌症的女性中更高。我们在此应用中专注于卵巢癌,因为FR α在90%的非粘液上皮性卵巢肿瘤中过表达,在其他肿瘤中表达水平低得多;因此,我们预计更有可能设计和优化使用这些患者的血清检测FR α的检测方法;因为卵巢癌是最难诊断和治疗的人类疾病之一。我们的方法将是设计、开发和优化定量分析来测量这些分析物,并将每种分析应用于存档的、治疗前收集的30例卵巢癌患者(15例早期)和30例非癌症女性的血清,这些患者参加了梅奥诊所的病例对照研究。在生物标志物发现的初始阶段,我们的目的是评估我们的分析是否可以通过验证病例肿瘤中的FR α表达水平和无癌症对照组的对照血清中FR α表达水平来真实检测分析物。这项研究产生的数据,如果如我们预期的那样是阳性的,将成为将这些分析应用于其他肿瘤类型的更大规模分析的基础,这些分析有几个目的,包括评估诊断潜力,这是发现生物标志物的最终目标。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Keith L. Knutson其他文献
T-cell immune cluster analysis using CyTOF identifies unique subgroups of patients with acute myeloid leukemia
利用飞行时间质谱流式细胞技术(CyTOF)进行的T细胞免疫聚类分析确定了急性髓系白血病患者的独特亚组
- DOI:
10.1182/bloodadvances.2024014553 - 发表时间:
2025-01-28 - 期刊:
- 影响因子:7.100
- 作者:
Talha Badar;Keith L. Knutson;James Foran;Naseema Gangat;Kevin D. Pavelko;Scott H. Kaufmann;Mark R. Litzow;Hemant Murthy;Davitte Cogen;Margaret Ushman;Arini Arsana;Aref Al-Kali;Hassan Alkhateeb;Ayalew Tefferi;Mrinal Patnaik;Mithun Shah - 通讯作者:
Mithun Shah
Erratum to: Emergence of immune escape variant of mammary tumors that has distinct proteomic profile and a reduced ability to induce “danger signals”
- DOI:
10.1007/s10549-006-9163-6 - 发表时间:
2006-03-16 - 期刊:
- 影响因子:3.000
- 作者:
Masoud H. Manjili;Hilal Arnouk;Keith L. Knutson;Maciej Kmieciak;Mary L. Disis;John R. Subjeck;A. Latif Kazim - 通讯作者:
A. Latif Kazim
RETRACTED ARTICLE: Targeted immune therapy of ovarian cancer
- DOI:
10.1007/s10555-014-9540-2 - 发表时间:
2014-12-30 - 期刊:
- 影响因子:8.700
- 作者:
Keith L. Knutson;Lavakumar Karyampudi;Purushottam Lamichhane;Claudia Preston - 通讯作者:
Claudia Preston
CD4 regulatory T cells in human cancer pathogenesis
- DOI:
10.1007/s00262-006-0194-y - 发表时间:
2006-07-04 - 期刊:
- 影响因子:5.100
- 作者:
Keith L. Knutson;Mary L. Disis;Lupe G. Salazar - 通讯作者:
Lupe G. Salazar
Keith L. Knutson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Keith L. Knutson', 18)}}的其他基金
Analysis of serum folate receptor and antibody level for ovarian cancer detection
卵巢癌检测血清叶酸受体及抗体水平分析
- 批准号:
7288266 - 财政年份:2006
- 资助金额:
$ 7.4万 - 项目类别:
HLA classl complex expression in breast cancer immunity
乳腺癌免疫中HLA classl复合物的表达
- 批准号:
7069061 - 财政年份:2005
- 资助金额:
$ 7.4万 - 项目类别:
HLA classl complex expression in breast cancer immunity
乳腺癌免疫中HLA classl复合物的表达
- 批准号:
7587413 - 财政年份:2005
- 资助金额:
$ 7.4万 - 项目类别:
HLA class l complex expression in breast cancer immunity
乳腺癌免疫中 HLA I 类复合物的表达
- 批准号:
7229604 - 财政年份:2005
- 资助金额:
$ 7.4万 - 项目类别:
HLA class l complex expression in breast cancer immunity
乳腺癌免疫中 HLA I 类复合物的表达
- 批准号:
7414086 - 财政年份:2005
- 资助金额:
$ 7.4万 - 项目类别:
HLA class l complex expression in breast cancer immunity
乳腺癌免疫中 HLA I 类复合物的表达
- 批准号:
6906817 - 财政年份:2005
- 资助金额:
$ 7.4万 - 项目类别:
Tumor rejection antigens induced via epitope spreading
通过表位扩散诱导肿瘤排斥抗原
- 批准号:
6725807 - 财政年份:2004
- 资助金额:
$ 7.4万 - 项目类别:
相似海外基金
FAIRClinical: FAIR-ification of Supplementary Data to Support Clinical Research
FAIRClinical:补充数据的 FAIR 化以支持临床研究
- 批准号:
EP/Y036395/1 - 财政年份:2024
- 资助金额:
$ 7.4万 - 项目类别:
Research Grant
Optimizing integration of veterinary clinical research findings with human health systems to improve strategies for early detection and intervention
优化兽医临床研究结果与人类健康系统的整合,以改进早期检测和干预策略
- 批准号:
10764456 - 财政年份:2023
- 资助金额:
$ 7.4万 - 项目类别:
The IDeA State Consortium for a Clinical Research Resource Center: Increasing Clinical Trials in IDeA States through Communication of Opportunities, Effective Marketing, and WorkforceDevelopment
IDeA 州临床研究资源中心联盟:通过机会交流、有效营销和劳动力发展增加 IDeA 州的临床试验
- 批准号:
10715568 - 财政年份:2023
- 资助金额:
$ 7.4万 - 项目类别:
The Mayo Clinic NeuroNEXT Clinical Research Site
梅奥诊所 NeuroNEXT 临床研究网站
- 批准号:
10743328 - 财政年份:2023
- 资助金额:
$ 7.4万 - 项目类别:
Addressing Underperformance in Clinical Trial Enrollments: Development of a Clinical Trial Toolkit and Expansion of the Clinical Research Footprint
解决临床试验注册表现不佳的问题:开发临床试验工具包并扩大临床研究足迹
- 批准号:
10638813 - 财政年份:2023
- 资助金额:
$ 7.4万 - 项目类别:
Improving Multicultural Engagement in Clinical Research through Partnership with Federally Qualified Health Centers and Community Health Worker Programs
通过与联邦合格的健康中心和社区卫生工作者计划合作,改善临床研究中的多元文化参与
- 批准号:
10823828 - 财政年份:2023
- 资助金额:
$ 7.4万 - 项目类别:
The Minnesota TMD IMPACT Collaborative: Integrating Basic/Clinical Research Efforts and Training to Improve Clinical Care
明尼苏达州 TMD IMPACT 协作:整合基础/临床研究工作和培训以改善临床护理
- 批准号:
10828665 - 财政年份:2023
- 资助金额:
$ 7.4万 - 项目类别:
Promoting a Culture Of Innovation, Mentorship, Diversity and Opportunity in NCI Sponsored Clinical Research: NCI Research Specialist (Clinician Scientist) Award Application of Janice M. Mehnert, M.D.
在 NCI 资助的临床研究中促进创新、指导、多样性和机会文化:Janice M. Mehnert 医学博士的 NCI 研究专家(临床科学家)奖申请
- 批准号:
10721095 - 财政年份:2023
- 资助金额:
$ 7.4万 - 项目类别:
Clinical Research Center for REstoration of NEural-based Function in the Real World (RENEW)
现实世界神经功能恢复临床研究中心 (RENEW)
- 批准号:
10795328 - 财政年份:2023
- 资助金额:
$ 7.4万 - 项目类别:
Mentoring Scientists for Careers in HIV Translational Clinical Research
指导科学家从事艾滋病毒转化临床研究
- 批准号:
10762827 - 财政年份:2023
- 资助金额:
$ 7.4万 - 项目类别: